Artificial Pancreas Systems Market: Favourable Healthcare Insurance Policies in North America to Boost Adoption of Advanced Diabetes Treatment Options: North America and Europe Industry Analysis and Opportunity Assessment, 2016-2026

March 2017 •
121 pages •
Report ID: 4833623 •
Format: PDF

Summary
Table of contents

Diabetes Type 1 segment is likely to prevail over Diabetes Type 2 segment in the North America and Europe artificial pancreas systems market

The Diabetes Type 1 segment was estimated to account for a little more than 95% market share in terms of value in the North America and Europe artificial pancreas systems market by 2016 end and is expected to experience an increase of more than 200 BPS in its market share by 2026 over 2016. The Diabetes Type 1 segment is expected to register high Y-o-Y growth rates throughout the forecast period. Revenue contribution of this segment is projected to increase at a CAGR of 12.9% over the forecast period to reach more than US$ 250 Mn by 2026.

On the other hand the Diabetes Type 2 segment is expected to register low Y-o-Y growth rates throughout the forecast period. Revenue contribution of this segment to the North America and Europe artificial pancreas systems market is expected to increase at a CAGR of 4.1% over the forecast period. The Diabetes Type 1 segment dominated the North America and Europe artificial pancreas systems market in revenue terms in 2015, and the trend is projected to continue throughout the forecast period. The Diabetes Type 2 segment is expected to remain the least attractive segment in the North America and Europe artificial pancreas systems market in revenue terms with a low market attractiveness index of 0.02 over the forecast period.

Alarming rise in population and economic burden of diabetes worldwide is anticipated to impact the artificial pancreas systems market in North America and Europe

Diabetes is one of the chronic and life-threatening diseases that affects a large part of the global population. Diabetes, also known as diabetes mellitus, is a metabolic disorder wherein the pancreas are either not able to produce insulin or the body is not able to utilise the existing insulin to metabolise glucose. Insulin is an essential secretion (hormone) of the body that metabolises glucose received by the body during and after a meal. An increasing burden of managing and controlling diabetes is the most important factor prompting demand for artificial pancreas systems among the global diabetic population.

Conventional systems used for diabetes management have many drawbacks including the need to take insulin injections at multiple times and recalibrating the CGM devices, thereby making management of diabetes quite tedious. However, artificial pancreas systems are designed to be more portable and user friendly. Artificial pancreas systems are technologically advanced. On the other hand, the conventional insulin pumps or CGM devices are large in size and thus, people have social and psychological stigma regarding conventional insulin devices, which motivates them to opt for artificial pancreas systems. This particular factor is creating a robust development in the North America and Europe artificial pancreas systems market.

Artificial pancreas systems are envisioned to deliver a complete system known as a closed loop system that mimics a pancreatic activity of maintaining blood glucose levels by coalescing several technologies including a glucose monitoring device, a glucose sensor with cutting-edge algorithm software and an insulin pump. Manufacturers are competing to provide such high-end artificial pancreas systems to attract diabetic patients who intend to improve diabetes management.

Diabetes Type 1 segment is projected to dominate the North America and Europe artificial pancreas systems market throughout the period of assessment

Diabetes Type 1 disease indication segment dominated the North America artificial pancreas systems market in revenue terms in 2015 and is projected to continue to do so throughout the forecast period, recording a market attractiveness index of 2.0. In Western and Eastern Europe this segment is expected to remain the dominant disease indication segment throughout the projected period.

Ahmad helps you find the right report:

+1 718 618 4302
Contact by email

FAQ

Testimonials

The market research advisor answered my questions quickly and professionally. ReportBuyer's team did their best to ensure that I felt comfortable before making the investment to purchase the report.

Cristian Nunez

Director of Corporate Development Chugach Alaska Corporation

My overall experience with ReportBuyer today has been very positive, and I must thank you for your patience (...). Also, the sample you sent me and the explanations provided were very helpful.

D. Lescuyer

Executive Vice President Oral Business at Skyepharma

The research specialist was very helpful, and proposed the best content for my needs. ReportBuyer also offered a great follow-up, thanks for everything !

P. Thompson

EMEA Managing Director

We were satisfied with the support that ReportBuyer's team provided. Thanks to their recommendations, the report we purchased provided exactly what we want.

Y. Wang

Business Analyst

We didn't have time to do the research internally, and thanks to ReportBuyer's team we were able to find the appropriate data.

S. Chen

Research Coordinator

I was impressed by the customer service: it was fast, responsive, and 100% professional !

D. Krivan

Market Research Analyst

The research specialist provided prompt and helpful service. He also followed up to ensure I had all the information to deliver my business development plan.

C. Adams

Senior Business Development Manager